CoChat

Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

Open access
Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., Becker, R. H. A. · 2015 · Diabetes, Obesity and Metabolism
Cited by 95

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aims: Two single‐dose studies were conducted in J apan and E urope to compare the pharmacokinetic ( PK ) and pharmacodynamic ( PD ) profiles of new insulin glargine 300 U/ml ( Gla‐300 ) and insulin glargine 100 U/ml ( Gla‐100 ) in people with type 1 diabetes mellitus. Methods: In two double‐blind, randomized, crossover studies, 18 J apanese participants (aged 20–65 years) and 24 E uropean participants (aged 18–65 years) with glycated haemoglobin levels ≤9.0% (≤75 mmol/mol) received single subcutaneous doses of Gla‐300 , 0.4, 0.6 and 0.9 U/kg (0.9 U/kg in the E uropean study only), and Gla‐100 , 0.4 U/kg. A 36‐h euglycaemic clamp procedure was performed after each dosing. Results: The serum insulin glargine concentration ( INS ) and glucose infusion rate ( GIR ) developed more gradually into more constant and prolonged profiles with Gla‐300 than with Gla‐100 . In support of this, the times to 50% of glargine exposure and insulin activity were longer for all Gla‐300 doses than for Gla‐100 during the 36‐h clamp period, indicating a more evenly distributed exposure and metabolic effect beyond 24 h. Exposure to insulin glargine and glucose utilization were lower with the 0.4 and 0.6 U/ml Gla‐300 doses in both studies compared with the 0.4 U/ml Gla‐100 dose. Glucose‐lowering activity was detected for up to 36 h with all doses of Gla‐300 . Conclusions: Single‐dose injections of Gla‐300 present more constant and prolonged PK and PD profiles compared with Gla‐100 , maintaining blood glucose control for up to 36 h in euglycaemic clamp settings in J apanese and E uropean participants with type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12415

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 95

Metadata

Authors
Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., & Becker, R. H. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-12-22
Volume
17
Issue
3
Pages
254-260
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2065510740
Cited by
95
References
3
FWCI
9.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. https://app.cochat.ai/papers/10.1111/dom.12415
The paper
Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., & Becker, R. H. A. (2015). Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12415

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.